Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cipla
Cantor Fitzgerald
US Department of Justice
AstraZeneca
McKesson

Generated: May 23, 2019

DrugPatentWatch Database Preview

TRILIPIX Drug Profile

« Back to Dashboard

When do Trilipix patents expire, and when can generic versions of Trilipix launch?

Trilipix is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has nineteen patent family members in eleven countries.

The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.

Drug patent expirations by year for TRILIPIX
Pharmacology for TRILIPIX
Synonyms for TRILIPIX
017F890
1034151-05-7
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropionic acid
2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid (Fenofibric acid)
2-[4-(4-Chlorobenzoyl)-phenoxy]-2-methylpropionic acid
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methyl-propanoic Acid
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate,2-hydroxyethyl(trimethyl)azanium
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic Acid (Fenofibric Acid)
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid choline salt
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic acid, 95%
2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid
2-Hydroxy-N,N,N-trimethylethanaminium 2-(-(4-chlorobenzoyl)phenoxy)-2- methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
2-methyl-((4'-4-chlorobenxoly)-2-phenoxy)propionic acid
2-methyl-((4'-p-chlorobenzoyl)-2-phenoxy)propionic acid
3320AC
42017-89-0
4BMH7IZT98
4CH-014888
856676-23-8
AB0011864
AB01563028_01
ABT 335
Abt 335;abt-335;abt335
ABT-335
AC-22277
AC1L228K
AJ-08119
AK117112
AKOS015889489
AKOS016010592
alpha 1081
AN-6566
API0000561
API0009427
API0025995
AS-10210
AX8069177
AX8245113
BCP22437
BCP28592
BDBM28700
BGF9MN2HU1
BRN 2058973
C17H15ClO4
CCG-213311
CCRIS 7302
CHEBI:83469
CHEMBL1201745
CHEMBL981
Choline fenofibrate
Choline fenofibrate (ABT-335)
Choline fenofibrate (USAN/INN)
Choline fenofibrate [USAN:INN]
CS-0893
CS-2965
CTK8E8257
D08890
DB13873
DTXSID50234939
DTXSID8041030
EINECS 255-626-9
Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-(4-(4- chlorobenzoyl)phenoxy)-2-methylpropanoic acid (1:1)
F1011
feno-fibric acid
Fenofibrate de choline
Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard
Fenofibrate Related Compound B, United States Pharmacopeia (USP) Reference Standard
FENOFIBRIC ACID
Fenofibric acid
Fenofibric acid (TN)
Fenofibric acid, analytical standard
FNF Acid
FT-0082391
FT-0600402
FT-0665026
GTPL2662
HIP0901
HY-14739
HY-B0760
I01-2052
J10251
JWAZHODZSADEHB-UHFFFAOYSA-M
KB-51864
KS-00000MR0
KS-00000R22
KS-1234
LF 153
LF 178 acid
LS-121251
M-1210
MCULE-1938576029
MolPort-000-002-475
MolPort-006-393-282
MQOBSOSZFYZQOK-UHFFFAOYSA-N
NSC 281318
NSC-281318
NSC281318
Procetofenic acid
Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-
Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-
RL03621
RT-012006
s4527
SC-15796
SCHEMBL16377
ST24040685
ST2416089
ST50998899
UNII-4BMH7IZT98
Unii-4bmh7izt98 BFenofibrate de choline
UNII-BGF9MN2HU1
W-106287
W-5743
ZINC1984

US Patents and Regulatory Information for TRILIPIX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-001 Dec 15, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-002 Dec 15, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TRILIPIX
Drugname Dosage Strength RLD Date
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe ➤ Try a Free Trial

International Patents for TRILIPIX

Supplementary Protection Certificates for TRILIPIX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1758590 300907 Netherlands ➤ Try a Free Trial PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT
1746976 CA 2017 00030 Denmark ➤ Try a Free Trial PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
1746976 2017C/027 Belgium ➤ Try a Free Trial PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
0050793 94C0009 Belgium ➤ Try a Free Trial PRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214
1746976 LUC00026 Luxembourg ➤ Try a Free Trial PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Accenture
Fish and Richardson
McKinsey
UBS
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.